A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007.-MedSci.cn

A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007.

Yap, TA; Dhawan, MS; Hendifar, AE; Maio, M; Owonikoko, TK; Quintela-Fandino, M; Shapira, R; Saraf, S; Qiu, P; Jin, F; Gozman, A; Levine, DA